Related Experiment Videos
[Corticosteroid treatment of asthma]
Schweizerische Medizinische Wochenschrift
|February 9, 1980
Summary
Inhaled beclomethasone dipropionate (BDP) offers effective asthma treatment comparable to oral prednisolone but with fewer systemic side effects. Its use is linked to minimal local issues like oral candidiasis, without evidence of promoting lung infections or bronchial damage.
Area of Science:
- Pulmonology
- Pharmacology
- Allergy & Immunology
Context:
- Asthma management often involves corticosteroids.
- Oral corticosteroids carry significant systemic side effect risks.
- Inhaled corticosteroids offer a localized treatment alternative.
Purpose:
- To evaluate the efficacy and safety of inhaled beclomethasone dipropionate (BDP) for asthma treatment.
- To compare BDP's effectiveness and side effect profile with oral corticosteroids.
- To assess the risk of local side effects and lung damage associated with inhaled BDP.
Summary:
- Inhaled beclomethasone dipropionate (BDP) demonstrates efficacy in asthma treatment, comparable to 5-10 mg of daily oral prednisolone.
- BDP treatment avoids the systemic side effects common with oral corticosteroid therapy.
- The primary local side effect observed is oral candidiasis; no evidence suggests BDP causes lung infections or bronchial epithelial damage.
Impact:
- Inhaled BDP provides an effective and safer alternative for long-term asthma management.
- Reduced systemic side effects improve patient adherence and quality of life.
- Further supports the use of inhaled corticosteroids in respiratory medicine.